Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02152033 · ClinicalTrials.gov registry record · NA

Home-based Continuing Care for Young Adults Leaving Residential Substance Abuse Treatment

A NA study of Substance Use Disorders, sponsored by Treatment Research Institute.

Completed
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT02152033: Completed NA study of Substance Use Disorders, sponsored by Treatment Research Institute.

NCT02152033 is a NA study of Substance Use Disorders that has completed, run by Treatment Research Institute. The registered enrollment target is 30 participants, below the 500-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02152033, a NA study of Substance Use Disorders, has completed, sponsored by Treatment Research Institute.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this project is to develop and test a Home-based Continuing Care intervention that will help parents support the recovery of their Young Adult (YA) child who is leaving residential substance abuse treatment. The two phase pilot study will 1) interview 50 parents and 50 YAs recruited from residential treatment programs and from parent groups to inform the development of the intervention and 2) conduct a two-arm pilot study that will recruit a maximum of 20 parents and their young adult children into one of two conditions (Home-based Continuing Care \[HCC\] intervention group or Services as Usual \[SAU\] comparison group) with the main goal of determining whether conducting such an intervention is acceptable and sustainable, and to collect preliminary efficacy data. We hypothesize that pilot testing will indicate that: (a) HCC is acceptable and potentially sustainable; (b) conducting a randomized clinical trial is feasible, and (c) the magnitude of outcomes from HCC will be clinically meaningful.

Primary Outcome

Young Adult participants will complete a Timeline Follow Back (Baseline, 16 week and 32 week follow-ups) and provide a urine sample to be tested for drug and alcohol use (Baseline, Weekly, 16 week and 32 week follow-ups).

Conditions Studied

Interventions

  • BEHAVIORAL Services as Usual
  • BEHAVIORAL Home-based Continuing Care

Study Locations (1)

Pennsylvania

  • Family Training Program - Philadelphia

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2014-07
Est. Completion 2016-09
Phase NA
Treatment Research Institute

18 total trials

What the finished NCT02152033 record still lists

NCT02152033 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 500-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Substance Use Disorders appearing as the primary indexed condition, and to 2 interventions - of which Services as Usual is the first listed.

NCT02152033 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02152033 about?

NCT02152033 is a clinical study titled "Home-based Continuing Care for Young Adults Leaving Residential Substance Abuse Treatment". The purpose of this project is to develop and test a Home-based Continuing Care intervention that will help parents support the recovery of their Young Adult (YA) child who is leaving residential substance abuse treatment. The two phase pilot study will 1) interview 50 parents and 50 YAs recruited f...

What is the current status of trial NCT02152033?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2014-07. Estimated completion is 2016-09.

What conditions does trial NCT02152033 study?

This clinical trial studies the following conditions: Substance Use Disorders.

What interventions are being tested in trial NCT02152033?

The interventions under investigation include: Services as Usual (BEHAVIORAL), Home-based Continuing Care (BEHAVIORAL).

Who is sponsoring clinical trial NCT02152033?

This trial is sponsored by Treatment Research Institute, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02152033 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Substance Use Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02152033's enrollment target sits among peer trials

30 77th of 93 higher than 14 of 93 other Substance Use Disorders trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Substance Use Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02152033, the US trial registry maintained by the National Library of Medicine. NCT02152033 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.